Nearly all those who have Medicare Advantage plans must deal with prior authorization. Now more prior authorization issues are appearing with Part D prescription drugs.

The FDA has approved HemiClor (12.5 mg chlorthalidone) tablets for the treatment of hypertension in adults, to lower blood pressure.

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.

Critical changes are need to fix the time-wasting, care-delaying payer process. Highlighting prior authorization’s patient impact goes a long way. As state legislatures consider bills that could ...